Clinical StudiesA Severe, Refractory Case of Mucous Membrane Pemphigoid After Treatment With Pembrolizumab: Brief CommunicationBezinelli, Letícia Mello*; Eduardo, Fernanda P.*; Migliorati, Cesar A.†; Ferreira, Mariana H.*; Taranto, Patrícia‡; Sales, Diogo B.‡; Santi, Claudia G.§; Macarenco, Ricardo S.∥; Godoy, Claudia P.V.‡; Corrêa, Luciana¶; Buzaid, Antonio C.‡,#Author Information *Hospital Israelita Albert Einstein ‡Oncology Division ∥Department of Anatomic Pathology, Hospital Israelita Albert Einstein §Department of Dermatology ¶Department of General Pathology, School of Dentistry, University of São Paulo #Oncology Division, Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil †University of Florida College of Dentistry, Gainesville, FL Reprints: Fernanda P. Eduardo, Centro de Oncologia-Hematologia Hospital Israelita Albert Einstein Av., Albert Einstein, 627/520, São Paulo CEP 05651-901, Brazil (e-mail: email@example.com). Journal of Immunotherapy: November/December 2019 - Volume 42 - Issue 9 - p 359-362 doi: 10.1097/CJI.0000000000000280 Buy Metrics Abstract Pembrolizumab is a humanized antibody that targets the programmed death-1 receptor expressed in T cells with high selectivity. This therapeutic is of great importance in cancer immunotherapy yet managing the potential immune-related adverse events remains a concern. Here, we report a rare case of mucous membrane pemphigoid in the oral mucosa, upper respiratory tract, and conjunctiva of a patient with ovarian adenocarcinoma without cutaneous manifestation, which persisted even after pembrolizumab discontinuation. A brief review of pembrolizumab-related bullous pemphigoid cases is presented and possible mechanisms underlying these lesions are discussed. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.